Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Hangzhou Bio-Sincerity Pharma-Tech Co. Ltd. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, showing that the company's current filings are being reviewed in different specialized segments of the biotech field. This distribution suggests that the company is pursuing multiple distinct pharmaceutical or biological innovations simultaneously.
The busiest examiner for the portfolio is ARCORIA, PAUL JOSEPH, who is managing 1 pending office action. With a busiest examiner pending count of 1 and a total of 2 pending office actions, the workload is evenly distributed across the 2 distinct examiners. This arrangement prevents any single examiner from having a dominant influence over the company's entire pending pipeline, providing a more balanced prosecution environment.
Practitioners should be aware that the use of 2 distinct art units within the Biotechnology & Pharmaceuticals area may involve different examination timelines and technical standards. Managing 2 pending office actions across separate units requires a coordinated strategy to ensure that the company's overall patent goals are met. The lack of concentration under a single examiner allows for independent progress on each matter, reducing the impact of a single examiner's potential objections.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843662 | PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES | ARCORIA, PAUL JOSEPH | — |
| 18843289 | HISTAMINE H3 RECEPTOR ANTAGONISTS AND THEIR PHARMACEUTICAL USES | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843289 | HISTAMINE H3 RECEPTOR ANTAGONISTS AND THEIR PHARMACEUTICAL USES | OH, TAYLOR V | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843662 | PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES | ARCORIA, PAUL JOSEPH | 1621 | §112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18843289 | HISTAMINE H3 RECEPTOR ANTAGONISTS AND THEIR PHARMACEUTICAL USES | OH, TAYLOR V | 1625 | §112 | Non-Final OA | — | Pending | Sep 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Bio-Sincerity Pharma-Tech Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Paul Joseph Arcoria has the most, with 1 of Hangzhou Bio-Sincerity Pharma-Tech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
